S-1: bioAffinity Technologies Files for Resale of 1.63 Million Common Shares Following Recent Private Placement

bioAffinity Technologies is registering for the resale of up to 1.63 million shares of its common stock by selling stockholders after a recent $2.5 million private placement.

Summary

• bioAffinity Technologies has filed a registration statement for the resale of up to 1,632,000 shares of its common stock.
• The shares are to be resold by selling stockholders, including investors from a recent private placement and designees of the placement agent, WallachBeth Capital LLC.
• The registration covers 1,600,000 shares issuable upon exercise of common warrants and 32,000 shares issuable upon exercise of placement agent warrants.
• bioAffinity will not receive any proceeds from the resale of these shares, but will receive proceeds from the cash exercise of the warrants.
• The company intends to use the proceeds from any cash exercise of the warrants for working capital purposes.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol BIAF, and its tradeable warrants are listed under the symbol BIAFW.
• On April 3, 2024, the last reported sale price of the company's common stock was $2.24 per share, and the tradeable warrants were $0.69 per warrant.
• The company recently raised $2.5 million in gross proceeds from a registered direct offering and concurrent private placement in March 2024.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It primarily describes a financial transaction and does not contain overtly positive or negative language.

Positives

• The company will receive proceeds from the cash exercise of the warrants.
• The company intends to use the proceeds from any cash exercise of the warrants for working capital purposes.

Negatives

• The company will not receive any proceeds from the resale of these shares.
• Resales of the company's common stock in the public market may cause the market price of the common stock to fall.
• The offering may cause the trading price of the company's common stock to decrease.

Risks

• Resales of the company's common stock in the public market may cause the market price of the common stock to fall.
• Investors who buy shares at different times will likely pay different prices.
• The offering may cause the trading price of the company's common stock to decrease.
• The company's management will have broad discretion over the use of the net proceeds.

Future Outlook

The company intends to use the proceeds from any cash exercise of the warrants for working capital purposes.

Industry Context

This announcement is a standard financial procedure for companies that have recently completed a private placement and are obligated to register the resale of the securities issued in that placement.

Stakeholder Impact

• Existing shareholders may experience dilution.
• The market price of the company's common stock could be affected by resales of the registered shares.

Next Steps

• The selling stockholders may offer and sell the shares of common stock from time to time through public or private transactions.
• The company will use commercially reasonable efforts to maintain the effectiveness of the registration statement.

Key Dates

Keywords

common stock, resale, warrants, bioAffinity Technologies, private placement, offering, BIAF